HydroxychloroquineQT prolongation due to off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2022年 / 1912卷 / 1期

关键词：

D O I：

10.1007/s40278-022-17937-x

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：234 / 234

相关论文

共 50 条

[41] Paclitaxel/vemurafenibMyelosuppression and off-label use: case report
Reactions Weekly, 2022, 1888 (1) : 292 - 292
[42] NivolumabFever following off-label use: case report
Reactions Weekly, 2016, 1601 (1) : 186 - 186
[43] FavipiravirNephrotoxicity following off-label use: case report
Reactions Weekly, 2022, 1929 (1) : 283 - 283
[44] BevacizumabRetinal breaks and off-label use: case report
Reactions Weekly, 2022, 1924 (1) : 120 - 120
[45] Mirtazapine/pregabalinDelirium and off-label use: case report
Reactions Weekly, 2024, 2029 (1) : 384 - 384
[46] DexamfetamineHypertension following off-label use: case report
Reactions Weekly, 2021, 1883 (1) : 150 - 150
[47] DexamethasoneHyperglycaemia following off-label use: case report
Reactions Weekly, 2022, 1896 (1) : 173 - 173
[48] DexamethasoneAspergillosis secondary to off-label use: case report
Reactions Weekly, 2022, 1935 (1) : 177 - 177
[49] TocilizumabAnaphylaxis following off-label use: case report
Reactions Weekly, 2021, 1865 (1) : 397 - 397
[50] MirtazapineTachyphylaxis following off-label use: case report
Reactions Weekly, 2018, 1703 (1) : 182 - 182

← 1 2 3 4 5 →